Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
brand:
Bystolic (1) ·
Caplyta (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Lovaza, Omtryg (1) ·
Namzaric (1) ·
Nuplazid (1) ·
Qelbree (1) ·
REL-1017 / esmethadone (investigational; not yet FDA-approved as of mid-2024) (1) ·
Rexulti (1) ·
Trintellix (US), Brintellix (formerly) (1) ·
Viibryd (1) ·
Zebeta (1)
classes:
5HT1A activity than aripiprazole (1) ·
5HT2A (1) ·
5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity (1) ·
Antidepressant (1) ·
Anxiolytic (1) ·
Atypical antipsychotic (2) ·
Beta Blocker (2) ·
Cardioselective (β1) (1) ·
Cardioselective (β1) + vasodilator (1) ·
Combined cholinesterase inhibitor + NMDA antagonist (1) ·
D2/5HT1A partial agonist with stronger α1A (1) ·
low-trapping) (1) ·
Multimodal antidepressant: SERT inhibitor + 5HT1A agonist + 5HT1B partial agonist + 5HT3/5HT7 antagonist (1) ·
NMDA receptor antagonist (uncompetitive (1) ·
non-stimulant ADHD agent (1) ·
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism) (1) ·
Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism (1) ·
Serotonin partial agonist reuptake inhibitor (SPARI) (1) ·
SNRI (1) ·
[[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (1) ·
[[:Category:Omega-3_fatty_acids|Omega-3 fatty acid]] (1)
mechanism:
None (4) ·
Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. (1) ·
Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) ·
Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) ·
'"`UNIQ--vote-0000004E-QINU`"' The EPA+DHA mix is biochemically and clinically distinct from icosapent ethyl'"`UNIQ--ref-0000004F-QINU`"'. (1)
uses:
ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) ·
Investigational for major depressive disorder; trials underway (phase 3 mixed results) (1) ·
Major depressive disorder in adults (FDA-approved 2011) (1) ·
Major depressive disorder in adults (FDA-approved 2013). Notable for evidence of cognitive benefit (processing speed) that distinguishes it from other antidepressants. (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1) ·
'"`UNIQ--vote-00000050-QINU`"' (1) ·
'"`UNIQ--vote-00000468-QINU`"' (1) ·
'"`UNIQ--vote-0000059D-QINU`"' (1) ·
'"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1)
starting dose:
None (1) ·
10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) ·
10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed (1) ·
2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) ·
34 mg PO once daily (1) ·
4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID) (1) ·
42 mg PO once daily with food (no titration) (1) ·
5 mg daily (1) ·
For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength (1) ·
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Trials use 25 mg or 50 mg PO daily (1)
preparations:
None (1) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) ·
1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters (1) ·
10 mg, 20 mg, 40 mg tablets (1) ·
10 mg, 34 mg capsules/tablets (1) ·
100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1) ·
2.5, 5, 10, 20 mg tabs (1) ·
42 mg capsules (1) ·
5 mg, 10 mg, 20 mg tablets (1) ·
5, 10 mg tabs (1) ·
7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) (1) ·
Investigational oral capsule (1)
fda max:
onset:
1–2 h (2) ·
4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) ·
ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1) ·
Antipsychotic effect over weeks (1) ·
Benefit over weeks of dosing (1) ·
Component effects accumulate over weeks (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Rapid (within 1 week in trials) (1) ·
Triglyceride lowering at 2-4 weeks; max at 8 weeks (1) ·
Typical antidepressant 4-6 week onset (1) ·
Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1)
duration: (Click arrow to add another value)
halflife:
9–12 h (1) ·
Not formally established (1) ·
Not well characterized; tissue incorporation over weeks'"`UNIQ--ref-00000051-QINU`"' (1) ·
~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) ·
~12 hours (1) ·
~18 hours (terminal) (1) ·
~25 hours (1) ·
~57 hours (parent), ~200 h (active metabolite) (1) ·
~60–80 h (memantine); ~70 h (donepezil) (1) ·
~66 hours (1) ·
~7 hours (1) ·
~91 hours (1)
bioavailability:
Adequate oral bioavailability with extended-release formulation (1) ·
Improved with food'"`UNIQ--ref-00000052-QINU`"' (1) ·
Limited but adequate; take with food (1) ·
Not characterized; oral dosing once daily (1) ·
Oral bioavailability suitable for daily dosing (1) ·
~100% both components (1) ·
~12% (extensive metabolizers); ~96% (poor metabolizers) (1) ·
~50% (highly variable) (1) ·
~72% (with food); much lower fasting (~36%) (1) ·
~75% (1) ·
~90% (low first-pass) (1) ·
~95% (1)
pregnancy:
Category C (3) ·
Investigational (1) ·
Limited data (1) ·
Limited data; avoid (1) ·
Limited data; National Pregnancy Registry available (1) ·
Limited data; National Pregnancy Registry for Atypical Antipsychotics (1) ·
Limited data; weigh benefits/risks (2) ·
Limited human data<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not relevant (geriatric problem) (1)
legal:
Investigational (1) ·
Rx (4) ·
Rx, '''not a controlled substance''' (no DEA scheduling) (1) ·
Rx-only (1) ·
Rx-only in US (3) ·
Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1)
Showing below up to 12 results in range #1 to #12.